← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
SMMT
Summit Therapeutics Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$17.55
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
SMR
NUSCALE POWER Corp
Valuation N/A
Industrials Risk 42 · Elevated
Price$8.61
Model IV—
P/IV—
Market implies +65.4%/yr vs model +50.0% · above model
SMX
SMX (Security Matters) Public Ltd Co
Valuation N/A
Industrials Risk 31 · Moderate
Price$16.69
Model IV—
P/IV—
Limited data — see page
SMXWW
SMX (Security Matters) Public Ltd Co
Valuation N/A
Industrials Risk 43 · Elevated
Price$0.02
Model IV—
P/IV—
Limited data — see page
SNAP
Snap Inc
Valuation N/A
Technology Risk 49 · Elevated
Price$5.68
Model IV—
P/IV—
Market implies +35.8%/yr vs model +8.0% · above model
SNDK
Sandisk Corp
Valuation N/A
Technology Risk 32 · Moderate
Price$1,633.35
Model IV—
P/IV—
Market implies +59.4%/yr vs model +9.9% · above model
SNDL
SNDL Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$1.34
Model IV—
P/IV—
Limited data — see page
SNDX
Syndax Pharmaceuticals Inc
Valuation N/A
Healthcare Risk 67 · High
Price$18.35
Model IV—
P/IV—
Market implies +18.0%/yr vs model +5.4% · above model
SNES
SenesTech, Inc.
Valuation N/A
Basic Materials Risk 28 · Moderate
Price$0.86
Model IV—
P/IV—
Market implies +33.6%/yr vs model +8.0% · above model
SNGX
SOLIGENIX, INC.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.36
Model IV—
P/IV—
Market implies +38.9%/yr vs model +15.0% · above model
SNN
SMITH & NEPHEW PLC
Valuation N/A
Healthcare Risk 27 · Moderate
Price$27.50
Model IV—
P/IV—
Limited data — see page
SNOW
Snowflake Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$322.98
Model IV—
P/IV—
Market implies +41.4%/yr vs model +8.0% · above model
SNSE
Sensei Biotherapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$25.96
Model IV—
P/IV—
Limited data — see page
SNTG
Sentage Holdings Inc.
Valuation N/A
Financial Services Risk 33 · Moderate
Price$1.76
Model IV—
P/IV—
Market implies +66.7%/yr vs model +2.0% · above model
SNTI
Senti Biosciences Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.31
Model IV—
P/IV—
Market implies +96.6%/yr vs model +2.0% · above model
SNY
Sanofi
Valuation N/A
Healthcare Risk 33 · Moderate
Price$42.40
Model IV—
P/IV—
Limited data — see page
SOC
Sable Offshore Corp.
Valuation N/A
Energy Risk 27 · Moderate
Price$5.17
Model IV—
P/IV—
Market implies +55.0%/yr vs model +4.0% · above model
SOCA
Solarius Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$10.35
Model IV—
P/IV—
Limited data — see page
SOCAU
Solarius Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$10.45
Model IV—
P/IV—
Limited data — see page
SOCAW
Solarius Capital Acquisition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$0.16
Model IV—
P/IV—
Limited data — see page
SOEZ
Franklin Solana Trust
Valuation N/A
Financial Services Risk 58 · Elevated
Price$17.91
Model IV—
P/IV—
Limited data — see page
SOFI
SoFi Technologies, Inc.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$17.07
Model IV—
P/IV—
Market implies +76.9%/yr vs model +25.8% · above model
SOGP
Sound Group Inc.
Valuation N/A
Technology Risk 31 · Moderate
Price$11.54
Model IV—
P/IV—
Market implies +50.8%/yr vs model +7.5% · above model
SONM
DNA X, Inc.
Valuation N/A
Technology Risk 43 · Elevated
Price$3.16
Model IV—
P/IV—
Market implies -30.0%/yr vs model +15.0% · below model
SONO
Sonos Inc
Valuation N/A
Technology Risk 37 · Moderate
Price$15.12
Model IV—
P/IV—
Market implies +29.7%/yr vs model +6.7% · above model
SONY
Sony Group Corp
Valuation N/A
Technology
Price$23.90
Model IV—
P/IV—
Limited data — see page
SOPH
SOPHiA GENETICS SA
Valuation N/A
Technology Risk 32 · Moderate
Price$7.87
Model IV—
P/IV—
Limited data — see page
SOR
SOURCE CAPITAL /DE/
Valuation N/A
Unknown
Price$46.56
Model IV—
P/IV—
Limited data — see page
SORA
AsiaStrategy
Valuation N/A
Industrials Risk 40 · Elevated
Price$2.24
Model IV—
P/IV—
Market implies +34.7%/yr vs model +2.0% · above model
SORN
Soren Acquisition Corp.
Valuation N/A
Financial Services
Price$10.02
Model IV—
P/IV—
Limited data — see page
SORNU
Soren Acquisition Corp.
Valuation N/A
Financial Services
Price$10.25
Model IV—
P/IV—
Limited data — see page
SORNW
Soren Acquisition Corp.
Valuation N/A
Financial Services
Price$0.26
Model IV—
P/IV—
Limited data — see page
SOS
SOS Ltd
Valuation N/A
Financial Services Risk 49 · Elevated
Price$0.76
Model IV—
P/IV—
Market implies -23.3%/yr vs model +2.0% · below model
SOTK
SONO TEK CORP
Valuation N/A
Industrials Risk 40 · Elevated
Price$4.59
Model IV—
P/IV—
Market implies +24.3%/yr vs model +2.0% · above model
SOUL
Soulpower Acquisition Corp.
Valuation N/A
Financial Services Risk 31 · Moderate
Price$10.46
Model IV—
P/IV—
Limited data — see page
SOUN
SOUNDHOUND AI, INC.
Valuation N/A
Technology Risk 31 · Moderate
Price$6.15
Model IV—
P/IV—
Market implies +28.4%/yr vs model +50.0% · below model
SOUNW
SOUNDHOUND AI, INC.
Valuation N/A
Technology Risk 75 · High
Price$1.01
Model IV—
P/IV—
Limited data — see page
SOWG
Sow Good Inc.
Valuation N/A
Consumer Defensive Risk 31 · Moderate
Price$3.25
Model IV—
P/IV—
Market implies +14.4%/yr vs model +15.0% · in line
SOYB
Teucrium Commodity Trust
Valuation N/A
Financial Services Risk 36 · Moderate
Price$27.50
Model IV—
P/IV—
Limited data — see page
SPAI
Safe Pro Group Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$4.43
Model IV—
P/IV—
Market implies +79.1%/yr vs model +2.0% · above model
SPCE
Virgin Galactic Holdings, Inc
Valuation N/A
Industrials Risk 48 · Elevated
Price$2.92
Model IV—
P/IV—
Market implies +81.1%/yr vs model +2.0% · above model
SPE
SPECIAL OPPORTUNITIES FUND, INC.
Valuation N/A
Unknown
Price$13.19
Model IV—
P/IV—
Limited data — see page
SPEG
Silver Pegasus Acquisition Corp.
Valuation N/A
Financial Services
Price$10.36
Model IV—
P/IV—
Limited data — see page
SPEGR
Silver Pegasus Acquisition Corp.
Valuation N/A
Financial Services
Price$0.20
Model IV—
P/IV—
Limited data — see page
SPEGU
Silver Pegasus Acquisition Corp.
Valuation N/A
Financial Services
Price$10.48
Model IV—
P/IV—
Limited data — see page
SPHL
SPRINGVIEW HOLDINGS LTD
Valuation N/A
Industrials Risk 27 · Moderate
Price$2.31
Model IV—
P/IV—
Market implies +55.9%/yr vs model +15.0% · above model
SPIR
Spire Global, Inc.
Valuation N/A
Communication Services Risk 46 · Elevated
Price$11.42
Model IV—
P/IV—
Market implies +38.7%/yr vs model +13.3% · above model
SPKL
Spark I Acquisition Corp
Valuation N/A
Financial Services Risk 27 · Moderate
Price$11.58
Model IV—
P/IV—
Limited data — see page
SPKLU
Spark I Acquisition Corp
Valuation N/A
Financial Services Risk 32 · Moderate
Price$12.42
Model IV—
P/IV—
Limited data — see page
SPKLW
Spark I Acquisition Corp
Valuation N/A
Financial Services Risk 33 · Moderate
Price$0.97
Model IV—
P/IV—
Limited data — see page
SPMA
Sound Point Meridian Capital, Inc.
Valuation N/A
Unknown
Price$25.16
Model IV—
P/IV—
Limited data — see page
SPMC
Sound Point Meridian Capital, Inc.
Valuation N/A
Unknown
Price$9.68
Model IV—
P/IV—
Limited data — see page
SPME
Sound Point Meridian Capital, Inc.
Valuation N/A
Unknown
Price$24.96
Model IV—
P/IV—
Limited data — see page
SPPP
SPROTT PHYSICAL PLATINUM & PALLADIUM TRUST
Valuation N/A
Financial Services Risk 33 · Moderate
Price$14.47
Model IV—
P/IV—
Limited data — see page
SPRB
SPRUCE BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$53.70
Model IV—
P/IV—
Market implies +33.9%/yr vs model +15.0% · above model
SPRC
SciSparc Ltd.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$5.08
Model IV—
P/IV—
Limited data — see page
SPRO
Spero Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.13
Model IV—
P/IV—
Market implies -2.7%/yr vs model +42.3% · below model
SPTX
Seaport Therapeutics, Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$23.34
Model IV—
P/IV—
Limited data — see page
SPXX
Nuveen S&P 500 Dynamic Overwrite Fund
Valuation N/A
Unknown
Price$18.95
Model IV—
P/IV—
Limited data — see page
SQM
CHEMICAL & MINING CO OF CHILE INC
Valuation N/A
Basic Materials Risk 36 · Moderate
Price$69.88
Model IV—
P/IV—
Limited data — see page